Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Alexion Pharm Inc (ALXN)

Alexion Pharm Inc (ALXN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Alexion Announces Positive Topline Results from Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Adults with Generalized Myasthenia Gravis (gMG)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced positive topline results from a Phase 3 study evaluating the safety and efficacy of ULTOMIRIS ® (ravulizumab-cwvz) in adults with generalized...

ALXN : 182.50 (+1.70%)
Honeywell International Inc. to Join the NASDAQ-100 Index Beginning July 21, 2021

NEW YORK, July 14, 2021 (GLOBE NEWSWIRE) -- Nasdaq (Nasdaq: NDAQ) today announced that Honeywell International Inc. (Nasdaq: HON), will become a component of the NASDAQ-100 Index ® (Nasdaq: NDX), the...

HON : 228.32 (+0.63%)
ALXN : 182.50 (+1.70%)
NDAQ : 77.70 (+0.41%)
Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021

Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced new Phase 2 safety and tolerability data for CAEL-101, a potentially first-in-class amyloid fibril targeted therapy,...

ALXN : 182.50 (+1.70%)
FBIO : 1.7200 (-1.15%)
Alexion Announces FDA Approval of ULTOMIRIS® (ravulizumab-cwvz) for Children and Adolescents with Paroxysmal Nocturnal Hemoglobinuria (PNH)

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of ULTOMIRIS ® (ravulizumab-cwvz) to include children (one month...

ALXN : 182.50 (+1.70%)
Caelum and Alexion Announce Upcoming CAEL-101 Data Presentations at the European Hematology Association Congress 2021

Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that two abstracts on CAEL-101, a potentially first-in-class amyloid fibril targeted therapy, have been accepted for e-poster...

ALXN : 182.50 (+1.70%)
FBIO : 1.7200 (-1.15%)
Alexion Announces Upcoming Data Presentations at the 26th European Hematology Association Virtual Congress

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that five abstracts have been accepted for presentation at the 26 th annual European Hematology Association (EHA) 2021 virtual Congress, taking...

ALXN : 182.50 (+1.70%)
Alexion Shareholders Approve Acquisition by AstraZeneca

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that its shareholders have voted to adopt and approve the previously announced agreement to be acquired by AstraZeneca at a special meeting...

ALXN : 182.50 (+1.70%)
Alexion Reports First Quarter 2021 Results

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced financial results for the first quarter of 2021. Total revenues in the first quarter were $1,636.5 million, a 13 percent increase compared to...

ALXN : 182.50 (+1.70%)
UPDATED Alexion to Report First Quarter 2021 Results on Friday, April 30, 2021

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on April...

ALXN : 182.50 (+1.70%)
Alexion to Report First Quarter 2021 Results on Monday, May 3, 2021

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that the Company will report its financial results for the first quarter ended March 31, 2021 before the US financial markets open on May 3,...

ALXN : 182.50 (+1.70%)

Barchart Exclusives

How To Profit From The Latest Corporate Spinoffs: A Guide For Investors In 2025
How to navigate corporate spinoffs. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar